Add as bookmark

Refractory Multiple Myeloma – New FDA Approved Treatment 2022

by Ipshita Ghoshal(more info)

listed in cancer, originally published in issue 289 - September 2023


Originally Published in:


Multiple myeloma is one of the rarest cancers. In 2022, an estimated 34,470 cases of multiple myeloma were recorded in the United States. The death toll went up to 12,640 in the United States. Only 55% of people can survive up to 5 years after a cancer diagnosis. Most people struggle to live that long after being diagnosed with multiple myeloma.


Myeloma Image 1 Clipboard


According to the International Myeloma Foundation, relapses of multiple myeloma are common. The majority of patients experience remissions and relapses numerous times over the course of their illness.

The initial remission stage may last two to three years or longer for those with no additional risk factors.

According to a study in 2016, relapse rates in 511 patients with multiple myeloma after therapy from 2006 to 2014 were examined.

16 percent of the individuals had an early relapse within a year. But 84% either experienced a relapse within a year or had none at the time of the follow-up.

Researchers keep on studying the disease to develop various refractory multiple myeloma treatments to increase the relative survival rate of patients.

Also in India, cervical cancer is the second most common form of cancer in women, which is another reason for deaths. Click the link to find all the information related the cervical cancer and also the best cancer hospitals in India.


More Inormation


Are you interested in learning about the latest relapsed multiple myeloma treatment? Keep reading ahead!! 

For better treatment opportunities for you or your loved ones, find the best blood cancer hospitals in India and the costs here.

More About: New Multiple Myeloma Relapse Treatment

On 25th October 2022, the FDA approved a new treatment for relapsed refractory multiple Myeloma. Tecvayli (Teclistamab) got accelerated approval from the FDA. Tecvayli is approved for those who did not respond positively to four or more treatment cycles.

As per the FDA, this is the first BCMA-directed CD3 T-cell engager drug. This drug for myeloma relapse works by sticking to certain kinds of T cells that attack the cancer cells after finding them.Click here to check the best cancer hospital in Mumbai, Delhi and Hyderabad.

The Approval of Tecvayli (Teclistamab)

Teclistamab was evaluated in the study named MajesTEC-1. The study sample comprised 110 patients who had already received three prior therapies. The study's main objective was to determine the overall response rate and the percentage of patients who showed reduced symptoms of relapsed multiple myeloma. 

After the study, it was found that the overall response rate was 61.8%. In 90.6% of the patients, the positive response lasted more than six months. The positive response lasted for more than nine months in patients with excellent ORR. 

Hence Tecvayli was granted accelerated approval.

What are the Adverse Effects of Tecvayli?

There are a few side effects linked to Tecvayli, as observed among 20% of the patients who were administered Tecvayli during the Clinical study:

  • Pyrexia; 
  • CRS;
  • Musculoskeletal pain;
  • Reactions at the injection site;
  • Fatigue;
  • Infection in the Upper respiratory tract;
  • Headache and Nausea;
  • Pneumonia; 
  • Diarrhea

Safety Information Concerning Tecvayli

  • Tecvayli has a Boxed Warning for cytokine release syndrome, a disease in which the body releases an excessive amount of the inflammatory proteins known as cytokines;
  • Hepatotoxicity, infections, neutropenia, hypersensitivity, and embryo-fetal toxicity are among the warnings and precautions related to Tecvayli. 

Cancer is a life-threatening disease and a major cause of death worldwide. Its treatment is impossible to afford for the poor. Click to read through a detailed guide about free cancer treatment in India.


Acknowledgement Citation

Originally Published on:



  1. No Article Comments available

Post Your Comments:

About Ipshita Ghoshal

Ipshita Ghoshal is an MBA professional with a passion for writing and research. She has experience contributing to the medical industry, having been a medical content writer at Clinicspots. Ipshita understands the complexities of healthcare and has used her expertise to author numerous articles on topics ranging from preventative care to understanding complex treatments. Her in-depth knowledge gives her the ability to communicate complicated information in simple language that can be easily understood by readers. Ipshita's work has helped educate countless individuals on important medical topics, providing them with invaluable information that could improve their healthcare decisions. Ipshita Ghoshal may be contacted via 

  • nutrition and cancer

    by Sandra Goodman PhD The latest scientific research regarding Nutrition and Cancer. Full details at

  • Super Patch Wellbeing

    Super Patches – a most revolutionary advance in wellbeing strategies in the history of medicine


    The FLEXXICORE exercise revolution: transform your fitness regime with 2 exhilarating exercisers

  • Water for Health

    Specialist online health store focused on hydration, body pH balance and quality nutrition.

  • Seaweed as Superfood

    Comprehensive nutrient balance found in no other natural food but seaweed: colon health, weight loss


    Aromatherapy creams & candles. Heal naturally No side effects. Holistic treatments, powerful courses

  • College of Ayurveda UK

    Diploma in Āyurvedic Medicine, 4-year self-paced distant learning program in Āyurvedic medicine.

  • Flower essences online

    Fine quality flower essences international ranges to help promote vitality and emotional well-being.

  • mycology research MRL

    MRL markets mushroom products food grade US & Netherlands GMP standards. Health Professional Videos

  • Liposomal Nutrients

    Optimum system for nutrient delivery to cells - fully bioavailable vitamins absorbed and metabolised

  • radical spirituality

    UK publisher of rejected knowledge in areas of esoteric thought and radical streams of spirituality.

  • Beginner's Guide to ME

    Essential reading for people/carers with ME/CFS serious debilitating illness. Counteracts bad advice

  • Supercoherence-System

    Supercoherence master code can restore each human to their pristine pure state at the speed of light

  • June Sayer Homeopathy

    Training Academy Homeopathy Nutrition Reiki, Distant Learning. Diet, Health Screening, Detox, Stress

top of the page